K Number
K211406
Device Name
OASIS MRI System
Date Cleared
2021-10-07

(154 days)

Product Code
Regulation Number
892.1000
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The OASIS MRI System is an imaging device, and is intended to provide the physician with physiological and clinical information, obtained non-invasively and without the use of ionizing radiation. The MR system produces transverse, coronal, sagittal, oblique, and curved cross-sectional images that display the internal structure of the head, body, or extremities. The images produced by the MR system reflect the spatial distribution of protons (hydrogen nuclei) exhibiting magnetic resonance. The NMR properties that determine the image appearance are proton density, spin-lattice relaxation time (T), spin-spin relaxation time (T2), and flow. When interpreted by a trained physician, these images provide information that can be useful in diagnosis determination.
Device Description
The OASIS is a Magnetic Resonance Imaging System that utilizes a 1.2 Tesla superconducting maqnet in a qantry design.
More Information

Not Found

No
The summary explicitly states "Mentions AI, DNN, or ML: Not Found" and the descriptions of the device and performance studies do not mention any AI/ML components or methodologies.

No
Explanation: The device is described as an "imaging device" and its purpose is to "provide the physician with physiological and clinical information" and "useful in diagnosis determination." It produces images that display internal body structures. There is no indication that it treats or cures a disease or condition.

Yes
The "Intended Use / Indications for Use" states that the images, "When interpreted by a trained physician, provide information that can be useful in diagnosis determination." Additionally, "Performance Testing - Bench" confirms that new features "perform as intended for diagnostic use."

No

The device description explicitly states it is a "Magnetic Resonance Imaging System that utilizes a 1.2 Tesla superconducting magnet in a gantry design," indicating it includes significant hardware components beyond just software.

Based on the provided information, the OASIS MRI System is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use clearly states that the device is an "imaging device" that provides "physiological and clinical information" through "non-invasive" means. It produces images of the internal structure of the body.
  • Mechanism of Action: The device utilizes Magnetic Resonance Imaging (MRI) to create images based on the magnetic properties of protons within the body. This is a physical imaging technique, not a test performed on biological samples outside the body.
  • IVD Definition: In Vitro Diagnostics (IVDs) are medical devices used to perform tests on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. The OASIS MRI System does not perform such tests on biological samples.

The OASIS MRI System is a medical imaging device used for diagnostic purposes, but it falls under a different regulatory category than IVDs.

N/A

Intended Use / Indications for Use

The OASIS MRI System is an imaging device, and is intended to provide the physician with physiological and clinical information, obtained non-invasively and without the use of ionizing radiation. The MR system produces transverse, coronal, sagittal, oblique, and curved cross-sectional images that display the internal structure of the head, body, or extremities. The images produced by the MR system reflect the spatial distribution of protons (hydrogen nuclei) exhibiting magnetic resonance. The NMR properties that determine the image appearance are proton density, spin-lattice relaxation time (T1), spin-spin relaxation time (T2), and flow. When interpreted by a trained physician, these images provide information that can be useful in diagnosis determination.

Product codes (comma separated list FDA assigned to the subject device)

LNH

Device Description

The OASIS is a Magnetic Resonance Imaging System that utilizes a 1.2 Tesla superconducting maqnet in a qantry design.

Mentions image processing

Yes

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Magnetic Resonance Imaging (MRI)

Anatomical Site

Head, Body, Spine, Extremities

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Physician

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

New software functions were tested basically according to the documents which were described in Test Report for IEC 62304. In addition, tests for following new software functions were conducted, they include:

  • Test Report: IP-Recon
  • Test Report: IP-Scan
  • Test Report: AutoPose Spine
  • Test Report: AutoClip
    Clinical images were collected and analyzed, to ensure that images from the new feature meet user needs. As a result of the analysis: Clinical image examples are provided for each applicable new feature, which are WIT Head/Neck Coil, WIT Head Attachment, WIT Head/Neck Attachment, WIT Neck Attachment and WIT Torso Coil A, WIT Torso Coil B and new software functions, and that we judged to be sufficient to evaluate clinical usability.

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

The OASIS MRI System was subjected to the following laboratory testing.

  • NEMA MS-1-2008 (R2014), Determination of Signal-to-Noise Ratio (SNR) In Diagnostic Magnetic ● Resonance Imaging (All receiver coils)
  • NEMA MS 3-2008 (R2014), Determination of Image Uniformity in Diagnostic Magnetic ● Resonance Images (All receiver coils)
  • IEC 60601-1: 2005 + CORR. 1:2006 + CORR. 2:2007 + AM1:2012 ●
  • IEC 60601-1-2 Edition 4.0 2014-02. Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests
  • IEC 60601-2-33 Ed. 3.2 b:2015, Medical electrical equipment - Part 2-33: Particular requirements for the basic safety and essential performance of magnetic resonance equipment for medical diaanosis
  • IEC 62304 Ed.1.1:2015-06 CONSOLIDATED VERSION Medical device software - Software life cycle processes
    The revisions to the OASIS MRI System and standards will have no effect on the standards tests, which were conducted on the OASIS MRI System (K202030) and included in the original submission.
  • NEMA MS 2-2008 (R2014), Determination of Two-Dimensional Geometric Distortion in ● Diagnostic Magnetic Resonance Images
  • NEMA MS 4-2010, Acoustic Noise Measurement Procedure for Diagnosing Magnetic Resonance Imaging Devices
  • NEMA MS 5-2018, Determination of Slice Thickness in Diagnostic Resonance Imaging
  • NEMA MS 8-2016, Characterization of the Specific Absorption Rate (SAR) for Magnetic Resonance Imaging Systems
    New software functions were tested basically according to the documents which were described in Test Report for IEC 62304. In addition, tests for following new software functions were conducted, they include:
  • Test Report: IP-Recon
  • Test Report: IP-Scan
  • Test Report: AutoPose Spine
  • Test Report: AutoClip
    Clinical image examples are provided for each applicable new feature and or coil that we judged to be sufficient to evaluate clinical usability. Clinical image examples are provided for each applicable new feature, which are WIT Head/Neck Coil, WIT Head Attachment, WIT Head/Neck Attachment, WIT Neck Attachment and WIT Torso Coil A, WIT Torso Coil B and new software functions, and that we judged to be sufficient to evaluate clinical usability.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K202030

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 892.1000 Magnetic resonance diagnostic device.

(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.

0

October 7, 2021

Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health and Human Services logo. To the right of that is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

Hitachi Healthcare Americas % Mr. Aaron Pierce Director, RA/QA 1959 Summit Commerce Park TWINSBURG OH 44087

Re: K211406

Trade/Device Name: OASIS MRI System Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic resonance diagnostic device Regulatory Class: Class II Product Code: LNH Dated: August 25, 2021 Received: August 31, 2021

Dear Mr. Aaron Pierce:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmp/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see

1

https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For

Thalia T. Mills. Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known) K211406

Device Name OASIS MRI System Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2023

See PRA Statement below.

Indications for Use (Describe)

The OASIS MRI System is an imaging device, and is intended to provide the physician with physiological and clinical information, obtained non-invasively and without the use of ionizing radiation. The MR system produces transverse, coronal, sagittal, oblique, and curved cross-sectional images that display the internal structure of the head, body, or extremities. The images produced by the MR system reflect the spatial distribution of protons (hydrogen nuclei) exhibiting magnetic resonance. The NMR properties that determine the image appearance are proton density, spin-lattice relaxation time (T), spin-spin relaxation time (T2), and flow. When interpreted by a trained physician, these images provide information that can be useful in diagnosis determination.

Anatomical Region:Head, Body, Spine, Extremities
Nucleus excited:Proton
Diagnostic uses:T1, T2, proton density weighted imaging
Diffusion weighted imaging
MR Angiography
Image processing
Spectroscopy
Whole Body
Type of Use (Select one or both, as applicable)
> Prescription Use (Part 21 CFR 801 Subpart D)Over-The-Counter Use (21 CFR 801 Subpart C)
AAUWILIP ALL I APALRIFE BLARIP UPPREA

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

HITACHI
Inspire the Next

Section 5 510(k) Statement or Summary

K211406

Submitter Information

Submitter:Hitachi Healthcare Americas
1959 Summit Commerce Park
Twinsburg, Ohio 44087-2371
Contact:Aaron Pierce
Telephone number:330-425-1313
Telephone number:330-963-0749
E-mail:PierceA@hitachihealthcare.com
Date:April 23, 2021

Subject Device Name

Trade/Proprietary Name:OASIS MRI system
Regulation Number:21 CFR 892.1000
Regulation Name:System, Nuclear Magnetic Resonance Imaging
Product CodeLNH
ClassII
PanelRadiology

Predicate Device Name

Predicate Device(s):OASIS MRI System (K202030)
Regulation Number:21 CFR 892.1000
Regulation Name:System, Nuclear Magnetic Resonance Imaging
Product CodeLNH
ClassII
PanelRadiology

Indications for Use

The OASIS MRI System is an imaging device, and is intended to provide the physician with physiological and clinical information, obtained non-invasively and without the use of ionizing radiation. The MR system produces transverse, coronal, sagittal, oblique, and curved crosssectional images that display the internal structure of the head, body, or extremities. The images produced by the MR system reflect the spatial distribution of protons (hydrogen nuclei) exhibiting magnetic resonance. The NMR properties that determine the image appearance are proton density, spin-lattice relaxation time (T1), spin-spin relaxation time (T2), and flow. When interpreted by a trained physician, these images provide information that can be useful in diagnosis determination.

Anatomical Region:Head, Body, Spine, Extremities
Nucleus excited:Proton
Diagnostic uses:T1, T2, proton density weighted imaging
Diffusion weighted imaging
MR Angiography
Image processing
Spectroscopy
Whole Body

4

Image /page/4/Picture/0 description: The image shows the number 5-2 at the top. Below that is the Hitachi logo in bold black font. Underneath the logo is the text "Inspire the Next".

Device Description

Function

The OASIS is a Magnetic Resonance Imaging System that utilizes a 1.2 Tesla superconducting maqnet in a qantry design.

Scientific Concepts

Magnetic Resonance imaging (MRI) is based on the fact that certain atomic nuclei have electromagnetic properties that cause them to act as small spinning bar maqnets. The most ubiquitous of these nuclei is hydrogen, which makes it the primary nuclei currently used in maqnetic resonance imaging. When placed in a static maqnetic field, these nuclei assume a net orientation or alignment with the magnetic field, referred to as a net magnetization vector. The introduction of a short burst of radiofrequency (RF) excitation of a wavelength specific to the magnetic field strength and to the atomic nuclei under consideration can cause a re-orientation of the net magnetization vector. When the RF excitation is removed, the protons relax and return to their original vector. The rate of relaxation is exponential and varies with the character of the proton and its adjacent molecular environment. This re-orientation process is characterized by two exponential relaxation times, called T1 and T2. A RF emission or echo that can be measured accompanies these relaxation events.

The emissions are used to develop a representation of the relaxation events in a threedimensional matrix. Spatial localization is encoded into the echoes by varying the RF excitation, applying appropriate magnetic field gradients in the x, y, and z directions, and changing the direction and strength of these gradients. Images depicting the spatial distribution of the NMR characteristics can be reconstructed by using image processing techniques similar to those used in computed tomography.

Physical and Performance Characteristics

MRI is capable of producing high quality anatomical images without the associated risks of ionizing radiation. The biological properties that contribute to MR image contrast are different from those responsible for x-ray image contrast. In MR imaging, difference in proton density, blood flow, and T1 and T2 relaxation times can all contribute to image contrast. By varying the pulse sequence characteristics, the resulting images can emphasize T1, T2, proton density, or the molecular diffusion of water or other proton containing molecules. In addition the OASIS MR system has the Function of measuring spectroscopy.

Performance Evaluation

The OASIS MRI System is equivalent to the OASIS MRI (K202030) with the following exceptions:

  • Head Coil is no longer available.
  • Breast Support Kit 2 is available for previously cleared Breast Coil as an accessory. ●
  • WIT Spine Coil revision A which provides a MUX board which has a function to select elements.
  • WIT Head/Neck Coil, WIT Head Attachment, WIT Head/Neck Attachment, WIT Neck . Attachment, WIT Torso Coil A and WIT Torso Coil B are added.
  • . Application software is changed to V7.2E.
  • IP-Recon, IP-Scan, AutoPose Spine, AutoExam and AutoClip are available. ●

5

Image /page/5/Picture/0 description: The image shows the logo for Hitachi. The word "HITACHI" is written in large, bold, black letters. Below the word "HITACHI" is the phrase "Inspire the Next" in a smaller, black font. The letter "t" in "Next" has a red accent mark.

A rationale analysis was then conducted and the results are contained below.

Testing TypeRationale Analysis
Performance Testing - BenchPerformance bench testing was conducted on the applicable new features. Test data confirmed that each new feature
perform as intended for diagnostic use.
Performance Testing -
ClinicalClinical image examples are provided for each applicable new feature and or coil that we judged to be sufficient to evaluate
clinical usability.

Device Technological Characteristics

The control and image processing hardware and the base elements of the system software are identical to the predicate device. The OASIS MRI system is substantially equivalent to the OASIS MRI system (K202030). See tables below.

The technological characteristics in regards to hardware of the OASIS MRI system and the predicate are listed below:

ITEMOASIS (K202030)OASISDIFFERENCE
SystemStandards MetNEMA: MS 1, MS 2, MS 3, MS 4, MS 5, MS 8,
IEC: 60601-1, 60601-1-2, 60601-2-33, 62304NEMA: MS 1, MS 2, MS 3, MS 4, MS 5, MS 8,
IEC: 60601-1, 60601-1-2, 60601-2-33, 62304No
Magnet and
GantryType and Field
StrengthSuper-conducting open magnet, 1.2 TeslaSuper-conducting open magnet, 1.2 TeslaNo
Resonant Frequency49.39MHz ± 98 kHz49.39MHz ± 98 kHzNo
Gradient SystemGradient Strength33mT/m33mT/mNo
Slew Rate100 T/m/sec100 T/m/secNo
Rise Time300µsec to 30mT/m300µsec to 30mT/mNo
Audible Noise (MCAN)
Ambient63 dBA63 dBANo
Lpeak126.3 dBA126.3 dBANo
Leq119 dBA119 dBANo
RF SystemTransmitter channels22No
Peak Envelop Power18 kW18 kWNo
Duty Cycle85% (Gating max), 10% at full power85% (Gating max), 10% at full powerNo
RF receiver channel1616No
System Control
UnitUnit TypeIRCPIRCPNo

The hardware differences from the OASIS MRI system to the predicate device are analyzed in the table below:

Table 1 Hardware NSE Analysis

| FDA
Requirements | Analyze why any differences between the subject device and predicate(s) do not render the device NSE (e.g., does not
constitute a new intended use; and any differences in technological characteristics are accompanied by information that
demonstrates the device is as safe and effective as the predicate and do not raise different questions of safety and
effectiveness than the predicate ), affect safety or effectiveness, or raise different questions of safety and effectiveness (see
section 513(i)(1)(A) of the FD&C Act and 21 CFR 807.87(f)). | | | |
|-----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------|----------------------------------|
| Device
Modification
Summary | There is no hardware difference. | | | |
| Significant
Changes | □ Manufacturing Process | □ Labeling | □ Technology | □ Performance |
| | □ Engineering | □ Materials | □ Others | ☑ None (See rationale statement) |
| HITACHI
Rationale
Statement | There is no change in the hardware. So, safety and effectiveness of the device are same as OASIS (K202030). | | | |

6

Image /page/6/Picture/0 description: The image shows the Hitachi logo. The word "HITACHI" is in large, bold, black letters. Below it, in a smaller font, is the phrase "Inspire the Next" in black, with a red accent mark above the letter 't' in 'Next'. The logo is simple and modern.

The technological characteristics in regards to coils of the OASIS MRI system and the predicate are listed in the table below:

ITEMOASIS (K202030)OASISDIFFERENCE
RF CoilsTransmit CoilT/R BodyT/R BodyNo
Receiver CoilsHead Coil-See Table 2
Extremity CoilExtremity CoilNo
Wrist CoilWrist CoilNo
Shoulder CoilShoulder CoilNo
Multipurpose CoilMultipurpose CoilNo
Micro CoilMicro CoilNo
Foot/Ankle CoilFoot/Ankle CoilNo
Breast CoilBreast CoilNo
Breast Support Kit 2See Table 2
Large Flex CoilLarge Flex CoilNo
Extra Large Flex CoilExtra Large Flex CoilNo
WIT Spine CoilWIT Spine Coil (Rev.A)See Table 2
WIT Head/Neck CoilSee Table 2
WIT Head AttachmentSee Table 2
WIT Head/Neck AttachmentSee Table 2
WIT Neck AttachmentSee Table 2
WIT Torso Coil ASee Table 2
WIT Torso Coil BSee Table 2

The coil differences from the OASIS MRI system to the predicate device are analyzed in the table below:

Table 2 Coil Comparison Analysis
FDA
RequirementsAnalyze why any differences between the subject device and predicate(s) do not render the device NSE (e.g., does not
constitute a new intended use; and any differences in technological characteristics are accompanied by information that
demonstrates the device is as safe and effective as the predicate and do not raise different questions of safety and
effectiveness than the predicate ), affect safety or effectiveness, or raise different questions of safety and effectiveness (see
section 513(i)(1)(A) of the FD&C Act and 21 CFR 807.87(f)).
Device
Modification
Summary• Head Coil is no longer available.
• Breast Support Kit 2 is available for previously cleared Breast Coil as an accessory.
• WIT Spine Coil revision A which provides a MUX board which has a function to select elements.
• WIT Head/Neck Coil, WIT Head Attachment, WIT Head/Neck Attachment, WIT Neck Attachment, WIT Torso Coil A
and WIT Torso Coil B are added.
• WIT Torso Coil A and WIT Torso Coil B are added.
Significant
Changes□ Manufacturing Process□ Labeling□ Technology□ Performance
□ Engineering□ Materials□ Others☑ None (See rationale statement)
HITACHI
Rationale
StatementAdditional or revised coils do not constitute a new intended use. There are no significant changes in technological
characteristics. During transmitter coil operation, RF Coils are de-resonated by same scheme as OASIS (K202030).

7

Image /page/7/Picture/0 description: The image shows the Hitachi logo. The word "HITACHI" is written in large, bold, black letters. Below the word "HITACHI" is the phrase "Inspire the Next" in a smaller, black font. The letter "t" in the word "Next" has a red accent mark.

5-5

The technological characteristics in regards to changes in functionality of the OASIS MRI System as compared to the predicate are listed in the table below:

ITEMDIFFERENCESANALYSIS
Operating SystemNone.No
CPU PlatformNone.No
Application SoftwareGoing from V7.0D to V7.2E.See Table 3
Scan TasksAutoPose Spine is available.See Table 3
2D Processing TasksNone.No
3D Processing TasksAutoClip is available.See Table 3
Analysis TasksNone.No
Maintenance TasksNone.No
Viewport ToolsNone.No
Film, Archive ToolsNone.No
Network ToolsNone.No
Protocol EnhancementsIP-Recon, IP-Scan and AutoExam are available.See Table 3
Pulse SequencesNone.No

The functionality differences from the OASIS MRI System to the predicate device are analyzed in the table below. Features have been added since the predicate device through the Memo to File process.

Table 3 Functionality Comparison Analysis
FDA
RequirementsAnalyze why any differences between the subject device and predicate(s) do not render the device NSE (e.g., does not
constitute a new intended use; and any differences in technological characteristics are accompanied by information that
demonstrates the device is as safe and effective as the predicate and do not raise different questions of safety and
effectiveness than the predicate ), affect safety or effectiveness, or raise different questions of safety and effectiveness (see
section 513(i)(1)(A) of the FD&C Act and 21 CFR 807.87(f)).
Device
Modification
SummaryApplication software is changed to V7.2E. IP-Recon, IP-Scan, AutoPose Spine, AutoExam and AutoClip are available.
Significant
Changes□ Manufacturing Process □ Labeling □ Technology □ Performance □ Engineering □ Materials □ Others ☑ None (See rationale statement)
HITACHI
Rationale
StatementAdditional functions do not constitute a new intended use. There are no significant changes in technological characteristics.
So, safety and effectivity of the device are equivalent to the OASIS (K202030).

8

Substantial Equivalence

A summary decision was based on analysis of results in the table below:

Table 4 Rationale Analysis: OASIS MRI vs. Predicate
ITEMOverall Rationale Analysis
HardwareThere is no change in the hardware. So, safety and effectively of the device are same as OASIS (K202030).
CoilsAdditional or revised coils do not constitute a new intended use. There are no significant changes in technological
characteristics. During transmitter coil operation, RF Coils are de-resonated by same scheme as OASIS (K202030).
FunctionalityAdditional functions do not constitute a new intended use. There are no significant changes in technological characteristics.
So, safety and effectivity of the device are equivalent to the OASIS (K202030).

Therefore, based on a thorough analysis and comparison of the functions, scientific concepts. physical and performance characteristics, performance comparison and technological characteristics, the proposed OASIS MRI is considered substantially equivalent to the currently marketed predicate device in terms of design features, fundamental scientific technology, indications for use, and safety and effectiveness.

Summary of Non-Clinical Testing

The OASIS MRI System was subjected to the following laboratory testing.

  • NEMA MS-1-2008 (R2014), Determination of Signal-to-Noise Ratio (SNR) In Diagnostic Magnetic ● Resonance Imaging (All receiver coils)
  • NEMA MS 3-2008 (R2014), Determination of Image Uniformity in Diagnostic Magnetic ● Resonance Images (All receiver coils)
  • IEC 60601-1: 2005 + CORR. 1:2006 + CORR. 2:2007 + AM1:2012 ●
  • IEC 60601-1-2 Edition 4.0 2014-02. Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests
  • IEC 60601-2-33 Ed. 3.2 b:2015, Medical electrical equipment - Part 2-33: Particular requirements for the basic safety and essential performance of magnetic resonance equipment for medical diaanosis
  • . IEC 62304 Ed.1.1:2015-06 CONSOLIDATED VERSION Medical device software - Software life cycle processes

The revisions to the OASIS MRI System and standards will have no effect on the standards tests, which were conducted on the OASIS MRI System (K202030) and included in the original submission.

  • NEMA MS 2-2008 (R2014), Determination of Two-Dimensional Geometric Distortion in ● Diagnostic Magnetic Resonance Images
  • . NEMA MS 4-2010, Acoustic Noise Measurement Procedure for Diagnosing Magnetic Resonance Imaging Devices
  • . NEMA MS 5-2018, Determination of Slice Thickness in Diagnostic Resonance Imaging
  • . NEMA MS 8-2016, Characterization of the Specific Absorption Rate (SAR) for Magnetic Resonance Imaging Systems

New software functions were tested basically according to the documents which were described in Test Report for IEC 62304. In addition, tests for following new software functions were conducted, they include:

  • . Test Report: IP-Recon
  • . Test Report: IP-Scan
  • Test Report: AutoPose Spine ●
  • . Test Report: AutoClip

9

Image /page/9/Picture/0 description: The image shows the logo for Hitachi, with the words "Inspire the Next" underneath. Above the logo is the number "5-7". The logo is in black and white, and the text is in a simple, sans-serif font. The image is likely from a document or presentation.

Summary of Clinical Testing

Clinical images were collected and analyzed, to ensure that images from the new feature meet user needs. As a result of the analysis:

Testing TypeRationale Analysis
Performance Testing -
ClinicalClinical image examples are provided for each applicable new feature, which are WIT Head/Neck Coil, WIT Head Attachment, WIT Head/Neck Attachment, WIT Neck Attachment and WIT Torso Coil A, WIT Torso Coil B and new software functions, and that we judged to be sufficient to evaluate clinical usability.

Conclusions

It is the opinion of Hitachi, the OASIS MRI system is substantially equivalent with respect to hardware, base elements of the software, safety, effectiveness, and functionality to the OASIS MRI System (K202030).